Loading data for IMMX — first visit, this takes a few seconds.
Immix Biopharma, Inc.
12.14 -0.56 (-4.41%)
- Marktkapitalisierung
- $868.5M
- Volumen
- 1.19M
- Nächster Ergebnistermin
- Nov 6, 2026
Immix Biopharma, Inc. (IMMX) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$0,18 | $0,00 | +18.18% |
Kennzahlen
- Geld
- 12.19
- Marktkapitalisierung
- 868M
- Umsatz (TTM)
- n/a
- Nettogewinn (TTM)
- -39.9M
- 0.20
- -0.88
- n/a
- -13.29
- KBV (TTM)
- 3.79
- KUV (TTM)
- n/a
- Termin Quartalszahlen
- Nov 6, 2026
- Brief
- 15.42
- Volumen
- 1,190,506
- Ø Vol. (20D)
- 1,853,887
- Eröffnung
- 12.86
- Vortagesschluss
- 12.70
- Tagesspanne
- 12.02 - 13.29
- 52-Wk Range
- 1.94 - 15.10
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Immix Biopharma, Inc.
Profil ansehen →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Branche Biotechnology
Sektor Healthcare
IPO Datum Dec 16, 2021
Mitarbeiter 21
Börse NasdaqCM
Tickersymbol IMMX
Website https://www.immixbio.com